A luminescent oxygen channeling immunoassay for the determination of insulin in human plasma.
The authors describe a homogeneous, sensitive, and rapid bead-based sandwich immunoassay with a broad analytical range for quantifying insulin in human plasma. The assay was performed as a 2-step reaction by incubating the sample with a mixture of biotinylated anti-insulin antibody and beads covalently coated with anti-insulin antibody for 1 h. This was followed by incubation with beads covalently coated with streptavidin for 30 min. After the incubation steps, light generated from a chemiluminescent reaction within the beads was quantitated. The assay was run in 384-well plates with a sample volume of 5 microL. The analytical range extended from 1 to 10,000 pM. Intra-assay precision (% coefficient of variation) ranged from 1.9% to 3.8% for various insulin concentrations. Interassay precision ranged from 4.6% to 7.3%. Assay detection limit was 0.3 pM. There was no interference from moderate hemolysis (with hemoglobin up to 375 mg/dL), bilirubin (up to at least 50 mg/dL), triglyceride (up to at least 1000 mg/dL), biotin (up to at least 7.7 ng/mL), or ascorbic acid (up to 100 mg/dL). However, gross hemolysis did affect the assay. Comparable results were obtained for plasma (ethylenediamine tetra-acetic acid, citrate, and heparin treated) and serum. The correlation with enzyme-linked immunosorbent assay (ELISA) was good (y = 1.25x + 1.19, R(2) = 0.98). This method is convenient and represents an alternative to ELISA.
Poulsen
Fritz
F
Diabetes Research Unit, Novo Nordisk, Bagsvaerd, Denmark. fpo@novonordisk.com
Jensen
Kirsten Borres
KB
D002138:Calibration; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007004:Hypoglycemic Agents / Q000097:blood* / Q000276:immunology / Q000494:pharmacology; D007118:Immunoassay / Q000379:methods*; D007328:Insulin / Q000097:blood* / Q000276:immunology / Q000494:pharmacology; D007700:Kinetics; D008163:Luminescent Measurements; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D007004:Hypoglycemic Agents; D007328:Insulin